AR124574A1 - Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso - Google Patents

Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso

Info

Publication number
AR124574A1
AR124574A1 ARP220100014A ARP220100014A AR124574A1 AR 124574 A1 AR124574 A1 AR 124574A1 AR P220100014 A ARP220100014 A AR P220100014A AR P220100014 A ARP220100014 A AR P220100014A AR 124574 A1 AR124574 A1 AR 124574A1
Authority
AR
Argentina
Prior art keywords
methods
cystic fibrosis
modulators
regulatory protein
transmembrane conductance
Prior art date
Application number
ARP220100014A
Other languages
English (en)
Inventor
Andrew Bogdan
David Hardee
Timothy R Hodges
Henry Korman
Huan Li
- Schrimpf Michael R Qiu
Original Assignee
Abbvie Global Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Global Entpr Ltd filed Critical Abbvie Global Entpr Ltd
Publication of AR124574A1 publication Critical patent/AR124574A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención proporciona compuestos de fórmula (1) en donde R¹ tiene cualquiera de los valores definidos en la memoria descriptiva, y sales farmacéuticamente aceptables de estos, composiciones farmacéuticas que los comprenden y métodos para tratar la fibrosis quística mediante la administración de un compuesto de la invención.
ARP220100014A 2021-01-06 2022-01-05 Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso AR124574A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163134392P 2021-01-06 2021-01-06

Publications (1)

Publication Number Publication Date
AR124574A1 true AR124574A1 (es) 2023-04-12

Family

ID=80349654

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100014A AR124574A1 (es) 2021-01-06 2022-01-05 Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso

Country Status (6)

Country Link
US (2) US20220213041A1 (es)
JP (1) JP2022106285A (es)
AR (1) AR124574A1 (es)
TW (1) TW202241851A (es)
UY (1) UY39603A (es)
WO (1) WO2022150173A1 (es)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765347A4 (en) 2004-06-04 2008-10-01 Univ California COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE
ME02970B (me) 2004-06-24 2018-07-20 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
HUE025553T2 (en) 2007-05-25 2016-02-29 Vertex Pharma CFTR modulators
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
EP2231671B1 (en) 2007-12-13 2013-04-24 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20110074916A (ko) 2008-10-23 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 Ｎ-(4-(7-아자비시클로［2.2.1］헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
BR112013007907A2 (pt) 2010-10-08 2016-06-14 N30 Pharmaceuticals Inc novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
ES2716723T3 (es) 2011-09-20 2019-06-14 Univ North Carolina Chapel Hill Regulación de los canales de sodio por las proteínas PLUNC
WO2014180562A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
SG11201600891UA (en) 2013-08-08 2016-03-30 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
SG11201703391VA (en) 2014-10-31 2017-05-30 Abbvie S À R L Substituted chromanes and method of use
BR112017009194A2 (pt) 2014-10-31 2017-12-26 Abbvie Sarl tetra-hidropiranos substituídos e método de uso
JP2018516932A (ja) 2015-06-02 2018-06-28 アッヴィ・エス・ア・エール・エル 置換ピリジンおよび使用方法
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
PL3359541T3 (pl) 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
BR112018007145A2 (pt) 2015-10-09 2018-11-06 AbbVie S.à.r.l. ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
EP3448842A1 (en) 2016-04-26 2019-03-06 AbbVie S.À.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US20180133046A1 (en) 2016-11-17 2018-05-17 Osteodirit, Inc. Custom spinal orthosis, methodology and wear compliance
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
TW202241851A (zh) 2022-11-01
WO2022150173A1 (en) 2022-07-14
JP2022106285A (ja) 2022-07-19
US20220213041A1 (en) 2022-07-07
US20240043386A1 (en) 2024-02-08
UY39603A (es) 2022-07-29

Similar Documents

Publication Publication Date Title
ECSP19048759A (es) Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, y proceso para producir el modulador
AR118555A1 (es) Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
UY38093A (es) Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
UY38880A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
DOP2022000091A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
ECSP088296A (es) Compuestos terapéuticos
EA202191361A1 (ru) Способы лечения муковисцидоза
CO2019002618A2 (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
UY37941A (es) Derivados de bencimidazol y sus usos
ECSP23095485A (es) N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
CL2023000655A1 (es) Degradadores de helios basados en pequeñas moléculas de piperidinilo; y uso
CL2019000727A1 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
AR124574A1 (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
UY39604A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
AR126702A1 (es) Compuestos fosfolípidos y métodos de preparación y uso de los mismos
AR124430A1 (es) Inhibidores de arginasa y métodos de uso de ellos
EA202190707A1 (ru) Ингибиторы о-гликопротеин-2-ацетамидо-2-деокси-3-d-глюкопиранозидазы

Legal Events

Date Code Title Description
FB Suspension of granting procedure